Shiguang Liu, Tzu‐Hsuan Yeh, Vijay P. Singh, Sruti Shiva, Lindsay Krauland, Huanan Li, Pili Zhang, Kusum Kharbanda, Vladimir Ritov, Satdarshan P.S. Monga, Donald K. Scott, Patricia K. Eagon, Jaideep Behari – 26 October 2011 – The liver plays a central role in ethanol metabolism, and oxidative stress is implicated in alcohol‐mediated liver injury. β‐Catenin regulates hepatic metabolic zonation and adaptive response to oxidative stress. We hypothesized that β‐catenin regulates the hepatic response to ethanol ingestion.

Marc Lütgehetmann, Lida V. Mancke, Tassilo Volz, Martina Helbig, Lena Allweiss, Till Bornscheuer, Joerg M. Pollok, Ansgar W. Lohse, J. Petersen, Stephan Urban, Maura Dandri – 26 October 2011 – No specific drugs are currently available against hepatitis delta virus (HDV), a defective virus leading to the most severe form of chronic viral hepatitis in man. The lack of convenient HDV infection models has hampered the development of effective therapeutics.

Kui Li, Nan L. Li, Dahai Wei, Susan R. Pfeffer, Meiyun Fan, Lawrence M. Pfeffer – 26 October 2011 – Chemokines and inflammatory cytokines are key regulators of immunity and inflammation during viral infections. Hepatitis C virus (HCV) is a hepatotropic RNA virus frequently associated with chronic liver inflammation and hepatocellular carcinoma. Intrahepatic levels of chemokines and cytokines are elevated in chronic HCV infections, but the underlying mechanisms remain unclear.

Jason Grebely, Son Truong Pham, Gail V. Matthews, Kathy Petoumenos, Rowena A. Bull, Barbara Yeung, William Rawlinson, John Kaldor, Andrew Lloyd, Margaret Hellard, Gregory J. Dore, Peter A. White, on behalf of the ATAHC Study Group – 26 October 2011 – The purpose of the study was to evaluate reinfection and superinfection during treatment for recent hepatitis C virus (HCV). The Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of the natural history and treatment of recent HCV.

Rui M. Tostões, Sofia B. Leite, Margarida Serra, Janne Jensen, Petter Björquist, Manuel J. T. Carrondo, Catarina Brito, Paula M. Alves – 26 October 2011 – Primary cultures of human hepatocyte spheroids are a promising in vitro model for long‐term studies of hepatic metabolism and cytotoxicity. The lack of robust methodologies to culture cell spheroids, as well as a poor characterization of human hepatocyte spheroid architecture and liver‐specific functionality, have hampered a widespread adoption of this three‐dimensional culture format.

Katrin Friedbichler, Madeleine Themanns, Kristina M. Mueller, Michaela Schlederer, Jan‐Wilhelm Kornfeld, Luigi M. Terracciano, Andrey V. Kozlov, Susanne Haindl, Lukas Kenner, Thomas Kolbe, Mathias Mueller, Kenneth J. Snibson, Markus H. Heim, Richard Moriggl – 26 October 2011 – Persistently high levels of growth hormone (GH) can cause liver cancer. GH activates multiple signal‐transduction pathways, among them janus kinase (JAK) 2‐signal transducer and activator of transcription (STAT) 5 (signal transducer and activator of transcription 5).

Stefan G. Hübscher – 17 October 2011

Benjamin H. Friedman, Joshua H. Wolf, Liqing Wang, Mary E. Putt, Abraham Shaked, Jason D. Christie, Wayne W. Hancock, Kim M. Olthoff – 17 October 2011 – Early allograft dysfunction (EAD) occurring in the first week post‐liver transplantation is associated with increased graft failure and mortality and is believed to be largely due to ischemia/reperfusion injury.

Vinay Sundaram, Jawad Ahmad – 17 October 2011

Parsia A. Vagefi, Nancy L. Ascher, Chris E. Freise, Jennifer L. Dodge, John P. Roberts – 17 October 2011 – The demographics of patients in the United States who undergo living donor liver transplantation (LDLT) versus patients who undergo deceased donor liver transplantation (DDLT) are interesting with respect to the demographics of the donor service areas (DSAs). We examined adult recipients of primary, non–status 1 liver‐only transplants from 2003 to 2009. The likelihood of undergoing LDLT was compared to the likelihood of undergoing DDLT by multivariate logistic regression.